Nuvalent, Inc. NUVL
Super Investor & Insider
1
Fondi che lo detengono
#1313
Rank consenso
1.4%
% dei portafogli
$1.3M
Valore detenuto
| Fondo | % portaf. | Attività | Azioni | Valore |
|---|---|---|---|---|
| Polen Capital Management · Polen Capital Management | 0.01% | Add 100.41% | 12,744 | $1.3M |
Fondi: 13F-HR alla SEC. Insider: acquisti (P) e vendite (S) in borsa da SEC EDGAR, ultimi 12 mesi.
About
Nuvalent, Inc. is a clinical-stage biopharmaceutical company focused on developing precisely targeted therapies for patients with cancer. The company applies structure-based drug design and chemistry expertise to create small-molecule treatments aimed at clinically proven kinase targets, with an emphasis on improving s…
SectorHealthcare
ExchangeNASDAQ
IndustryBiotechnology
CountryUnited States
Employees234
TickerNUVL
Statistics
Market Cap$9.73B
Revenue (TTM)$0
Net Income-$425.4M
Net Margin—
EPS$-5.85
P/E-21.06
P/S—
P/B8.29
EV/EBITDA-20.41
ROE-41.2%
Dividend Yield—
Price$123.38
Data: Twelve Data · Revenue = mcap / P/S